Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01704859 · ClinicalTrials.gov registry record · NA
VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers
A NA study of Fractures, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 25,871
- Enrollment target
- 1
- Study location
NCT01704859: Completed NA study of Fractures, sponsored by Brigham and Women's Hospital.
NCT01704859 is a NA study of Fractures that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 25,871 participants, above the 9,057-participant average among 3 other Fractures trials with a reported enrollment target (186% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01704859, a NA study of Fractures, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 25,871 participants
- Enrollment target
- 1
- Study location
Study Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine (1) whether vitamin D reduces incident total, non-vertebral fractures, and hip fractures and (2) whether this reduction is modified by vitamin D levels
Primary Outcome
To determine whether vitamin D supplementation will reduce incident total, non-vertebral, and hip fractures according to annual questionnaires, medical record review, and fracture adjudication.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Vitamin D3
- DIETARY_SUPPLEMENT Vitamin D3 placebo
- DIETARY_SUPPLEMENT Fish oil placebo
- DRUG omega-3 fatty acids (fish oil)
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,871 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2022-11-23 |
| Phase | NA |
What the finished NCT01704859 record still lists
NCT01704859 is an interventional study that assigns participants to a tested intervention. Its 25,871 participants enrollment target places it among the larger protocols in the corpus, above the 9,057-participant average among 3 other Fractures trials with a reported enrollment target (186% higher).
The record links to 1 condition, with Fractures appearing as the primary indexed condition, and to 4 interventions - of which Vitamin D3 is the first listed.
NCT01704859 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01704859 about?
NCT01704859 is a clinical study titled "VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers". The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and...
What is the current status of trial NCT01704859?
This trial is currently completed. It is a NA study. The enrollment target is 25,871 participants. The study started on 2018-06-01. Estimated completion is 2022-11-23.
What conditions does trial NCT01704859 study?
This clinical trial studies the following conditions: Fractures.
What interventions are being tested in trial NCT01704859?
The interventions under investigation include: Vitamin D3 (DIETARY_SUPPLEMENT), Vitamin D3 placebo (DIETARY_SUPPLEMENT), Fish oil placebo (DIETARY_SUPPLEMENT), omega-3 fatty acids (fish oil) (DRUG).
Who is sponsoring clinical trial NCT01704859?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01704859 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fractures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone (VITAL)
ACTIVE NOT RECRUITING · NA
-
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
COMPLETED · Phase 3
-
Use of Ultrasound to Evaluate Clavicle Fractures in Pediatric Patients
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07300839 · 25,500 participants · Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
- NCT03175302 · 25,240 participants
PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI